The neuropeptide Y-ergic system: potential therapeutic target against bone loss with obesity treatments

References

• Bales CW, Buhr G. Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life. J Am Med Dir Assoc 2008;9(5):302-12
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Caffarelli C, Nuti R. Obesity and fracture risk. Clin Cases Miner Bone Metab 2014;11(1):9-14
   PubMedGoogle Scholar
• Bouxsein ML, Szulc P, Munoz F, et al. Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. J Bone Miner Res 2007;22(6):825-31
   PubMed Web of Science ®Google Scholar
• Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture in men and women: an epidemiologic perspective. J Bone Miner Res 2012;27(1):1-10
   PubMedGoogle Scholar
• Brzozowska MM, Sainsbury A, Eisman JA, et al. Bariatric surgery and bone loss: do we need to be concerned? Clinic Rev Bone Miner Metab 2014;12(4):207-27
   Google Scholar
• Brzozowska MM, Sainsbury A, Eisman JA, et al. Bariatric surgery, bone loss, obesity and possible mechanisms. Obes Rev 2013;14(1):52-67
   PubMed Web of Science ®Google Scholar
• Shapses SA, Sukumar D. Bone metabolism in obesity and weight loss. Annu Rev Nutr 2012;32:287-309
   PubMedGoogle Scholar
• Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med 2011;124(11):1043-50
   PubMed Web of Science ®Google Scholar
• Cipriani C, Pepe J, Piemonte S, et al. Vitamin D and its relationship with obesity and muscle. Int J Endocrinol 2014;2014:841248
   PubMed Web of Science ®Google Scholar
• Halade GV, El Jamali A, Williams PJ, et al. Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. Exp Gerontol 2011;46(1):43-52
   PubMed Web of Science ®Google Scholar
• Koster A, Penninx BW, Newman AB, et al. Lifestyle factors and incident mobility limitation in obese and non-obese older adults. Obesity (Silver Spring) 2007;15(12):3122-32
   PubMedGoogle Scholar
• Madigan M, Rosenblatt NJ, Grabiner MD. Obesity as a factor contributing to falls by older adults. Curr Obes Rep 2014;3:348-54
   PubMedGoogle Scholar
• Ren J, Waclawczyk A, Hartfield D, et al. Analysis of fall injuries by body mass index. South Med J 2014;107(5):294-300
   PubMed Web of Science ®Google Scholar
• Manini TM, Clark BC, Nalls MA, et al. Reduced physical activity increases intermuscular adipose tissue in healthy young adults. Am J Clin Nutr 2007;85(2):377-84
   PubMed Web of Science ®Google Scholar
• Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol 2014;2014:309570
   Google Scholar
• Compston JE, Flahive J, Hooven FH, et al. Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: global Longitudinal Study of Osteoporosis in Women (GLOW). Calcif Tissue Int 2014;94(2):223-31
   PubMedGoogle Scholar
• Mulholland Y, Nicokavoura E, Broom J, Rolland C. Very-low-energy diets and morbidity: a systematic review of longer-term evidence. Br J Nutr 2012;108(5):832-51
   PubMedGoogle Scholar
• Hunter GR, Plaisance EP, Fisher G. Weight loss and bone mineral density. Curr Opin Endocrinol Diabetes Obes 2014;21(5):358-62
   PubMedGoogle Scholar
• Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384(9945):766-81
   PubMed Web of Science ®Google Scholar
• Yulyaningsih E, Loh K, Lin S, et al. Pancreatic polypeptide controls energy homeostasis via Npy6r signaling in the suprachiasmatic nucleus in mice. Cell Metab 2014;19(1):58-72
   PubMedGoogle Scholar
• Sainsbury A, Zhang L. Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit. Obes Rev 2012;13(3):234-57
   PubMedGoogle Scholar
• Sainsbury A, Zhang L. Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit. Mol Cell Endocrinol 2010;316(2):109-19
   PubMedGoogle Scholar
• Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis 2014;5(1):4-14
   PubMedGoogle Scholar
• Ericsson A, Schalling M, McIntyre KR, et al. Detection of neuropeptide Y and its mRNA in megakaryocytes: enhanced levels in certain autoimmune mice. Proc Natl Acad Sci USA 1987;84(16):5585-9
   PubMedGoogle Scholar
• Hill EL, Turner R, Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 1991;44(3):747-55
   PubMedGoogle Scholar
• Ahmed M, Srinivasan GR, Theodorsson E, et al. Extraction and quantitation of neuropeptides in bone by radioimmunoassay. Regul Pept 1994;51(3):179-88
   PubMedGoogle Scholar
• Ahmed M, Bjurholm A, Kreicbergs A, Schultzberg M. Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine. Spine (Phila Pa 1976) 1993;18(2):268-73
   PubMed Web of Science ®Google Scholar
• Lindblad BE, Nielsen LB, Jespersen SM, et al. Vasoconstrictive action of neuropeptide Y in bone. The porcine tibia perfused in vivo. Acta Orthop Scand 1994;65(6):629-34
   PubMed Web of Science ®Google Scholar
• Sisask G, Bjurholm A, Ahmed M, Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J Auton Nerv Syst 1996;59(1-2):27-33
   PubMedGoogle Scholar
• Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100(2):197-207
   PubMed Web of Science ®Google Scholar
• Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002;109(7):915-21
   PubMedGoogle Scholar
• Baldock PA, Sainsbury A, Allison S, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res 2005;20(10):1851-7
   PubMedGoogle Scholar
• Allison SJ, Baldock PA, Enriquez RF, et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009;24(2):294-304
   PubMedGoogle Scholar
• Baldock PA, Lee NJ, Driessler F, et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 2009;4(12):e8415
   Google Scholar
• Matic I, Matthews BG, Kizivat T, et al. Bone-specific overexpression of NPY modulates osteogenesis. J Musculoskelet Neuronal Interact 2012;12(4):209-18
   PubMedGoogle Scholar
• Steppan CM, Crawford DT, Chidsey-Frink KL, et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92(1-3):73-8
   PubMed Web of Science ®Google Scholar
• Baldock PA, Allison S, McDonald MM, et al. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 2006;21(10):1600-7
   PubMedGoogle Scholar
• Lee NJ, Wong IP, Baldock PA, Herzog H. Leptin as an endocrine signal in bone. Curr Osteoporos Rep 2008;6(2):62-6
   PubMedGoogle Scholar
• Lin S, Boey D, Couzens M, et al. Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 2005;39(1):21-8
   PubMedGoogle Scholar
• Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999;11(4):1431-48
   PubMedGoogle Scholar
• Fetissov SO, Byrne LC, Hassani H, et al. Characterisation of neuropeptide Y Y2 and Y5 receptor expression in the mouse hypothalamus. J Comp Neurol 2004;470:256-65
   PubMed Web of Science ®Google Scholar
• Shi YC, Lin S, Castillo L, et al. Peripheral-specific y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity (Silver Spring) 2011;19(11):2137-48
   PubMedGoogle Scholar
• Hosaka H, Nagata A, Yoshida T, et al. Pancreatic polypeptide is secreted from and controls differentiation through its specific receptors in osteoblastic MC3T3-E1 cells. Peptides 2008;29(8):1390-5
   PubMedGoogle Scholar
• Teixeira L, Sousa DM, Nunes AF, et al. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J Cell Biochem 2009;107(5):908-16
   PubMedGoogle Scholar
• Lundberg P, Allison SJ, Lee NJ, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007;282(26):19082-91
   PubMedGoogle Scholar
• Allison SJ, Baldock P, Sainsbury A, et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem 2006;281(33):23436-44
   PubMedGoogle Scholar
• Shi YC, Lin S, Wong IP, et al. NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 2010;5(6):e11361
   Google Scholar
• Suzuki N, Okada K, Minami S, Wakabayashi I. Inhibitory effect of neuropeptide Y on growth hormone secretion in rats is mediated by both Y1 and Y2-receptor subtypes and abolished after anterolateral deafferentation of the medial basal hypothalamus. Regul Pept 1996;65(2):145-51
   PubMedGoogle Scholar
• Lin S, Lin EJ, Boey D, et al. Fasting inhibits the growth and reproductive axes via distinct Y2 and Y4 receptor-mediated pathways. Endocrinology 2007;148(5):2056-65
   PubMedGoogle Scholar
• Dumont Y, Fournier A, St-Pierre S, et al. Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol 1990;191(3):501-3
   PubMedGoogle Scholar
• Parker RM, Barnes NM. mRNA: detection by in situ and northern hybridization. Methods Mol Biol 1999;106:247-83
   PubMedGoogle Scholar
• Ferguson AV, Latchford KJ, Samson WK. The paraventricular nucleus of the hypothalamus - a potential target for integrative treatment of autonomic dysfunction. Expert Opin Ther Targets 2008;12(6):717-27
   PubMed Web of Science ®Google Scholar
• Igwe JC, Jiang X, Paic F, et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 2009;108(3):621-30
   PubMedGoogle Scholar
• Lee NJ, Nguyen AD, Enriquez RF, et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 2011;48(3):461-7
   PubMedGoogle Scholar
• Shi YC, Baldock PA. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone 2012;50(2):430-6
   PubMedGoogle Scholar
• Wheway J, Mackay CR, Newton RA, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005;202(11):1527-38
   PubMedGoogle Scholar
• Macia L, Yulyaningsih E, Pangon L, et al. Neuropeptide Y1 receptor in immune cells regulates inflammation and insulin resistance associated with diet-induced obesity. Diabetes 2012;61(12):3228-38
   PubMedGoogle Scholar
• Baldock PA, Allison SJ, Lundberg P, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007;282(26):19092-102
   PubMedGoogle Scholar
• Kurebayashi N, Sato M, Fujisawa T, et al. Regulation of neuropeptide Y Y1 receptor expression by bone morphogenetic protein 2 in C2C12 myoblasts. Biochem Biophys Res Commun 2013;439(4):506-10
   PubMedGoogle Scholar
• Lee NJ, Doyle KL, Sainsbury A, et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res 2010;25(8):1736-47
   PubMedGoogle Scholar
• Sousa DM, McDonald MM, Mikulec K, et al. Neuropeptide Y modulates fracture healing through Y1 receptor signaling. J Orthop Res 2013;31(10):1570-8
   PubMedGoogle Scholar
• Serhan CA, Ward PA. Molecular and cellular basis of inflammation: current inflammation research. Humana Press; Totowa, NJ: 1998
   Google Scholar
• Sainsbury A, Baldock PA, Schwarzer C, et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 2003;23(15):5225-33
   PubMedGoogle Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002;418:650-4
   PubMed Web of Science ®Google Scholar
• Wong IP, Driessler F, Khor EC, et al. Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS One 2012;7(7):e40038
   Google Scholar
• Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006;91(3):1027-33
   PubMed Web of Science ®Google Scholar
• Misra M, Prabhakaran R, Miller KK, et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J Clin Endocrinol Metab 2008;93(4):1292-7
   PubMedGoogle Scholar
• Utz AL, Lawson EA, Misra M, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 2008;43(1):135-9
   PubMedGoogle Scholar
• Wortley KE, Garcia K, Okamoto H, et al. Peptide YY regulates bone turnover in rodents. Gastroenterology 2007;133(5):1534-43
   PubMedGoogle Scholar
• Amini P, Cahill F, Wadden D, et al. Beneficial association of serum ghrelin and peptide YY with bone mineral density in the Newfoundland population. BMC Endocr Disord 2013;13(1):35
   PubMedGoogle Scholar
• Zittel TT, Zeeb B, Maier GW, et al. High prevalence of bone disorders after gastrectomy. Am J Surg 1997;174(4):431-8
   PubMedGoogle Scholar
• Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab 2010;95(1):159-66
   PubMed Web of Science ®Google Scholar
• Ott MT, Fanti P, Malluche HH, et al. Biochemical Evidence of Metabolic Bone Disease in Women Following Roux-Y Gastric Bypass for Morbid Obesity. Obes Surg 1992;2(4):341-8
   PubMedGoogle Scholar
• Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab 2004;89(3):1061-5
   PubMedGoogle Scholar
• Biagioni MF, Mendes AL, Nogueira CR, et al. Weight-reducing gastroplasty with Roux-en-Y gastric bypass: impact on vitamin D status and bone remodeling markers. Metab Syndr Relat Disord 2014;12(1):11-15
   PubMedGoogle Scholar
• Stein EM, Carrelli A, Young P, et al. Bariatric surgery results in cortical bone loss. J Clin Endocrinol Metab 2013;98(2):541-9
   PubMedGoogle Scholar
• Valderas JP, Padilla O, Solari S, et al. Feeding and bone turnover in gastric bypass. J Clin Endocrinol Metab 2014;99(2):491-7
   PubMedGoogle Scholar
• von Mach MA, Stoeckli R, Bilz S, et al. Changes in bone mineral content after surgical treatment of morbid obesity. Metabolism 2004;53(7):918-21
   PubMedGoogle Scholar
• Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 2008;93(10):3735-40
   PubMed Web of Science ®Google Scholar
• Carrasco F, Ruz M, Rojas P, et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg 2009;19(1):41-6
   PubMedGoogle Scholar
• Mahdy T, Atia S, Farid M, Adulatif A. Effect of Roux-en Y gastric bypass on bone metabolism in patients with morbid obesity: mansoura experiences. Obes Surg 2008;18(12):1526-31
   PubMedGoogle Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312(7041):1254-9
   PubMed Web of Science ®Google Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359(9321):1929-36
   PubMed Web of Science ®Google Scholar
• Nakamura KM, Haglind EG, Clowes JA, et al. Fracture risk following bariatric surgery: a population-based study. Osteoporos Int 2014;25(1):151-8
   PubMed Web of Science ®Google Scholar
• Brzozowska M, Sainsbury A, Eisman J, et al. Bariatric surgery and bone loss: do we need to be concerned? Clinic Rev Bone Miner Metab 2014;12(4):207-27
   Google Scholar
• Hage MP, El-Hajj Fuleihan G. Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporos Int 2014;25(2):423-39
   PubMedGoogle Scholar
• Rodríguez-Carmona Y, López-Alavez FJ, González-Garay AG, et al. Bone mineral density after bariatric surgery. A systematic review. Int J Surg 2014;12(9):976-82
   PubMedGoogle Scholar
• Yu EW. Bone metabolism after bariatric surgery. J Bone Miner Res 2014;29(7):1507-18
   PubMed Web of Science ®Google Scholar
• Scibora LM. Skeletal effects of bariatric surgery: examining bone loss, potential mechanisms and clinical relevance. Diabetes Obes Metab 2014;16(12):1204-13
   PubMedGoogle Scholar
• Goode LR, Brolin RE, Chowdhury HA, Shapses SA. Bone and gastric bypass surgery: effects of dietary calcium and vitamin D. Obes Res 2004;12(1):40-7
   PubMedGoogle Scholar
• Nogues X, Goday A, Pena MJ, et al. [Bone mass loss after sleeve gastrectomy: a prospective comparative study with gastric bypass]. Cir Esp 2010;88(2):103-9
   PubMedGoogle Scholar
• Pluskiewicz W, Buzga M, Holeczy P, et al. Bone mineral changes in spine and proximal femur in individual obese women after laparoscopic sleeve gastrectomy: a short-term study. Obes Surg 2012;22(7):1068-76
   PubMedGoogle Scholar
• Vilarrasa N, de Gordejuela AG, Gomez-Vaquero C, et al. Effect of bariatric surgery on bone mineral density: comparison of gastric bypass and sleeve gastrectomy. Obes Surg 2013;23(12):2086-91
   PubMedGoogle Scholar
• Ruiz-Tovar J, Oller I, Priego P, et al. Short- and mid-term changes in bone mineral density after laparoscopic sleeve gastrectomy. Obes Surg 2013;23(7):861-6
   PubMedGoogle Scholar
• Giusti V, Gasteyger C, Suter M, et al. Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up. Int J Obes (Lond) 2005;29(12):1429-35
   PubMedGoogle Scholar
• Pugnale N, Giusti V, Suter M, et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre-menopausal women. Int J Obes Relat Metab Disord 2003;27(1):110-16
   PubMedGoogle Scholar
• Mulholland Y, Nicokavoura E, Broom J, Rolland C. Very-low-energy diets and morbidity: a systematic review of longer-term evidence. Br J Nutr 2012;108(5):832-51
   PubMedGoogle Scholar
• Hamilton KC, Fisher G, Roy JL, et al. The effects of weight loss on relative bone mineral density in premenopausal women. Obesity (Silver Spring) 2013;21(3):441-8
   PubMedGoogle Scholar
• Jesudason D, Nordin BEC, Keogh J, Clifton P. Comparison of 2 weight-loss diets of different protein content on bone health: a randomized trial. Am J Clin Nutr 2013;98(5):1343-52
   PubMedGoogle Scholar
• Sweeney ME, Hill JO, Heller PA, et al. Severe vs moderate energy restriction with and without exercise in the treatment of obesity: efficiency of weight loss. Am J Clin Nutr 1993;57(2):127-34
   PubMedGoogle Scholar
• Beck B, Jhanwar-Uniyal M, Burlet A, et al. Rapid and localized alterations of neuropeptide Y in discrete hypothalamic nuclei with feeding status. Brain Res 1990;528(2):245-9
   PubMed Web of Science ®Google Scholar
• Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332(10):621-8
   PubMed Web of Science ®Google Scholar
• Hunter GR, Byrne NM. Physical activity and muscle function but not resting energy expenditure impact on weight gain. J Strength Cond Res 2005;19(1):225-30
   PubMed Web of Science ®Google Scholar
• Allison SJ, Baldock PA, Herzog H. The control of bone remodeling by neuropeptide Y receptors. Peptides 2007;28(2):320-5
   PubMedGoogle Scholar
• Boughton CK, Murphy KG. Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. Br J Pharmacol 2013;170(7):1333-48
   PubMedGoogle Scholar
• Sainsbury A, Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in bodyweight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 2002;99(13):8938-43
   PubMedGoogle Scholar
• Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 2002;51(12):3420-7
   PubMedGoogle Scholar
• Baldock P, Lin S, Zhang L, et al. Neuropeptide y attenuates stress-induced bone loss through suppression of noradrenaline circuits. J Bone Miner Res 2014;29(10):2238-49
   PubMed Web of Science ®Google Scholar
• Sousa DM, Baldock PA, Enriquez RF, et al. Neuropeptide Y Y1 receptor antagonism increases bone mass in mice. Bone 2012;51(1):8-16
   PubMedGoogle Scholar
• Zhang L, Macia L, Turner N, et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2010;34(2):357-73
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Morgan EF, Yeh OC. Bone mechanics. In: Krutz M, editor. Standard handbook of biomedical engineering and design. McGraw-Hill; New York: 2003
   Google Scholar
• Ross MH, Pawlina W. Histology: a text and atlas. Lippincott Williams & Wilkins; Philadelphia, PA: 2010
   Google Scholar
• Toombs RJ, Ducher G, Shepherd JA, De Souza MJ. The impact of recent technological advances on the trueness and precision of DXA to assess body composition. Obesity (Silver Spring) 2012;20(1):30-9
   PubMed Web of Science ®Google Scholar
• Knapp KM, Welsman JR, Hopkins SJ, et al. Obesity increases precision errors in dual-energy X-ray absorptiometry measurements. J Clin Densitom 2012;15(3):315-19
   PubMedGoogle Scholar
• Bolotin HH. DXA in vivo BMD methodology: an erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling. Bone 2007;41(1):138-54
   PubMedGoogle Scholar
• Blake GM, Fogelman I. How important are BMD accuracy errors for the clinical interpretation of DXA scans? J Bone Miner Res 2008;23(4):457-62
   PubMedGoogle Scholar
• Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005;21(7):1015-26
   PubMed Web of Science ®Google Scholar
• Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 2012;32(2):105-12
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24(1):23-57
   PubMed Web of Science ®Google Scholar
• Wheater G, Elshahaly M, Tuck SP, et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med 2013;11:201
   PubMed Web of Science ®Google Scholar
• Paul Chubb SA, Byrnes E, Manning L, et al. Reference intervals for bone turnover markers and their association with incident hip fractures in older men: the Health In Men Study. J Clin Endocrinol Metab 2014. [Epub ahead of print]
   Google Scholar
• Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31(1):57-61
   PubMed Web of Science ®Google Scholar
• Vesper HW. Analytical and preanalytical issues in measurement of biochemical bone markers. Lab Med 2005;36:424-9
   Google Scholar
• Lee KM, Lee MH, Chung CY, et al. Measurement of urinary N-telopeptides and serum C-telopeptides from type I collagen using a lateral flow-based immunoassay. Sensors (Basel) 2013;13(1):165-74
   Google Scholar
• Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature. Implant Dent 2009;18(6):492-500
   PubMedGoogle Scholar